Company intelligence / Profile preview

Cytograft Tissue Engineering

Ownership: Private
Development stage: Other

Overview

Cytograft demonstrated successful preclinical and early clinical results with its fully biological, tissue-engineered vascular grafts. The company’s “Lifeline” product showed promise as an alternative to synthetic grafts for hemodialysis access and bypass surgery, with advantages in biocompatibility and reduced infection risk. Allogeneic versions were successfully implanted in humans without immune rejection. However, the company is now inactive and did not reach full commercialization.

Therapeutic areas: NephrologyCardiovascular
Modalities: Cell therapyBiologicTissue-engineered grafts (including autologous and allogeneic constructs)
Industry: Biotech

Drug pipeline

1 asset

LifeGuard

Unknown

Partnerships

Collaborations with academic institutions for clinical research

Beyond the preview

Go deeper on Cytograft Tissue Engineering.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytograft Tissue Engineering.

Explore the full profile